Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.
Sermorelin is classified under the World Anti-Doping Agency’s Prohibited List (Section S2.2.4, Growth Hormone Releasing Factors), at all times, for tested athletes.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment that retains the full biological activity of the 44-amino-acid native hormone. A formulation of sermorelin held regulatory approval in the United States from 1990 under a different brand name, used as a provocative agent for evaluating pituitary growth hormone secretory capacity and in supporting growth hormone signaling in pediatric growth hormone insufficiency. That formulation was voluntarily discontinued from the market in 2008 for commercial reasons unrelated to safety or effectiveness, and sermorelin is now supplied strictly as a research compound.
This regulatory history gives sermorelin an unusually well-documented clinical research base relative to most peptides in this category, a point worth noting for research context, distinct from any claim about the research-only product supplied here.
Because sermorelin signals the pituitary rather than replacing GH directly, research has reported that it preserves the body’s own feedback regulation, a mechanistic distinction from direct GH administration that researchers frequently note when interpreting outcome data.
Sermorelin binds the GHRH receptor on pituitary somatotroph cells as a full agonist, stimulating synthesis and pulsatile release of growth hormone. Its short plasma half-life, roughly 10 to 20 minutes, since it lacks the enzymatic-resistance modifications found in longer-acting GHRH analogs, produces a brief, physiological GH pulse rather than a sustained elevation. That released GH subsequently drives IGF-1 production in the liver, the downstream hormone responsible for most of GH’s tissue-level effects.
No standardized research dosing protocol exists for the current research-only supply of sermorelin, and any research protocol, route, or dose is determined solely by the licensed researcher or practitioner and their institution.
For reference, published aging research has most often used subcutaneous administration timed to the evening, consistent with the body’s largest natural GH pulse during deep sleep. This reflects historical study design, not a recommended or current protocol.
For labs converting a professional’s own determined research dose into an accurate reconstitution volume, CellGenic’s calculator tool is open to any visitor, with no account required.
The most commonly reported effects in the sermorelin clinical literature are injection-site reactions and transient flushing, with joint pain and peripheral edema reported more frequently in older research populations. Because sermorelin raises GH and IGF-1, published research has monitored insulin sensitivity at sustained higher exposures, and researchers should establish baseline metabolic and IGF-1 values before and during any protocol.
Every CellGenic lot is manufactured under cGMP conditions and undergoes mycoplasma, sterility, identity, and potency testing prior to release. Certificates of Analysis are issued per batch and can be retrieved directly using your batch number.
Sermorelin is one of several peptides studied for their effect on the GH axis, distinguished by the receptor system they act. Sermorelin and CJC-1295 are both GHRH analogs acting on the GHRH receptor, while Ipamorelin is a growth hormone secretagogue acting on a separate receptor system. Because the two systems are independent, research has examined combining a GHRH analog with a secretagogue for a larger, more sustained GH pulse than either produces alone.
Certificates of Analysis, batch documentation, and pricing are available exclusively to verified physicians, clinic operators, and researchers.
Become a Provider → A CellGenic specialist will follow up within one business day. Once your account is verified, full pricing and Certificates of Analysis unlock automatically.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the active amino-terminal segment of endogenous growth hormone-releasing hormone (GHRH). Research indicates it binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release. It is intended strictly for in vitro laboratory experimentation.
These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.
CellGenic ships exclusively to Mexico, Argentina, Colombia, and Perú under local license. Verified-provider-only platform from CellGenic.